Please assess the completion status of the following clinical trial:

Trial Title: Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of Age

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female subjects between, and including 6-12 weeks of age at the time of the first vaccination.~* Subjects for whom the investigator believes that their parent(s)/guardian(s) can and will comply with the requirements of the protocol.~* Written or oral, signed or thumb-printed informed consent obtained from the parent(s)/guardian(s) of the child/ward.~* Free of any known or suspected health problems (as established by medical history and clinical examination before entering into the study).~* Born after a gestation period of \>= 36 to \<= 42 weeks.~Exclusion Criteria:~* Use of any investigational or non-registered product (drug or vaccine) other than the study vaccines within 30 days preceding the first dose of the study vaccines, or planned use during the study period.~* Concurrently participating in another clinical study, at any time during the study period.~* Chronic administration (defined as more than 14 days) of immunosuppressants or other immune-modifying drugs since birth.~* A family history of congenital or hereditary immunodeficiency.~* Any confirmed or suspected immunosuppressive or immunodeficient condition based on medical history and physical examination.~* Administration of immunoglobulins and/or any blood products since birth or planned administration during the study period (with the exception of hepatitis B immunoglobulins at birth).~* Previous vaccination against diphtheria, tetanus, pertussis, poliomyelitis, hepatitis B, Haemophilus influenzae type b and/or Streptococcus pneumoniae (with the exception of vaccines where the first dose can be given within the first two weeks of life).~* Planned administration/administration of a vaccine not foreseen by the study protocol during the period starting 30 days before each dose of vaccine and ending 7 days after Dose 1 and Dose 2 and 30 days after Dose 3.~* History of, or intercurrent diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, H. influenzae type b and rotavirus disease.~* History of allergic disease or reactions likely to be exacerbated by any component of the vaccines.~* History of any neurological disorders or seizures.~* Major congenital defects or serious chronic illness.~* Acute disease at the time of enrolment.~* Gastroenteritis within 7 days preceding the study vaccine administration.~* Any clinically significant history of chronic gastrointestinal disease including any uncorrected congenital malformation of the gastrointestinal tract, intussusception or other medical condition determined to be serious by the investigator.

- Gender: ALL
- Minimum Age: 6 Weeks
- Maximum Age: 12 Weeks
- Healthy Volunteers: t

Study Arms:
- Synflorix Clinical Lot & Infanrix Group (Type: EXPERIMENTAL): Subjects received 3 doses of the clinical lot of Synflorix TM (GSK1024850A) intramuscularly in the right thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 and 5 months of age in Malaysia or 2 and 5 months of age in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).
- Synflorix Commercial Lot Infanrix Group (Type: EXPERIMENTAL): Subjects received 3 doses of the commercial lot of Synflorix TM (GSK1024850A) intramuscularly in the lright thigh at 2-3-5 months of age (= study month 0, 1, 3) co-administered with a DTPa-combined vaccine (Infanrix hexa TM (at 2, 3 or 5 months of age in Malaysia or 2 and 5 months in Singapore) or Infanrix-IPV/Hib TM (at 3 months of age in Singapore)) intramuscularly in the left thigh and Rotarix TM orally at 2-3 months of age (= study month 0, 1).

Based on this trial design, predict the completion outcome and termination type (if applicable).